About Astellas
Astellas Pharma Canada is the Canadian branch of a Japanese pharmaceutical company. The company was formed in 2005 when Yamanouchi Pharmaceuticals merged with Fujisawa Pharmaceutical, which already had a Canadian branch. Since the merger, Astellas Pharma Canada has introduced new products and continues to build its pipeline. The company has about 110 employees in Canada and a total of 17,000 employees globally.
Strategic business challenges
Astellas Pharma Canada was facing multiple strategic inflection points: market and industry disruption, a need to drive accelerated growth and transform its business model, changing customer expectations, and talent challenges.
Primary challenge
The pharmaceutical industry has been changing rapidly over the past several years, and the COVID-19 pandemic significantly accelerated the pace of that change. During the pandemic, Astellas Pharma Canada went through a couple of rounds of downsizing and restructured its organization in order to navigate those changes and meet the industry demands. Today, with several new products set to launch over the next 18 months, they face the additional challenge of scaling up for this expected growth.
They also face a fundamentally different business environment post-COVID, unlike anything the organization has dealt with before. Total healthcare spending has fallen post-pandemic, and physicians are booked back-to-back with in-person and digital appointments, making it harder to break through and get their attention in traditional face-to-face meetings. Specialty treatments for rare conditions are the new competitive frontier, and Astellas is transforming itself to specialize in these cutting-edge therapies and compete in this dynamic market in order to bring value to patients.
Leadership Goals
- Transform the organization’s culture, in order to meet changing customer demands and navigate industry changes.
- Achieve accelerated growth, while launching new products under a new commercial and business model.

